RICE involved in research studies on BBC2 Horizon programmePublished on 13/05/2016
We are involved in most of the research studies included in the programme which aired on 11th May 2016 and are actively recruiting for several drug trials - please see details below;
BIOGEN ENGAGE – Currently recruiting
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects with Early Alzheimer’s Disease.
The primary objective of the study is to evaluate the efficacy of monthly doses of aducanumab in slowing cognitive and functional impairment as measured by changes in the Clinical Dementia Rating (CDR-SB) score as compared with placebo in subjects with mild cognitive impairment and early AD.
Patients aged 50-85
Mini Mental State Examination (MMSE) score of 24-30
NOVARTIS BANNER – Not yet recruiting
A randomized, double-blind, placebo-controlled, two cohort parallel group study to evaluate the efficacy of CAD106 and CNP520 in participants at risk for the onset of clinical symptoms of Alzheimer’s disease.
The purpose of this study is to determine the effects of each of the two therapies given separately targeting amyloid on cognition, global clinical status and underlying pathology in participants at risk for the onset of clinical symptoms of AD. Cognitively unimpaired individuals with APOE4 HM genotype and age 60 to 75 years inclusive are selected as they represent a population at particularly high risk of progression to MCI due to AD and/or dementia due to AD.
Healthy volunteers aged 60-75 who carry the APOE4 HM genotype
Mini Mental State Examination (MMSE) score of 24 or above
GREAT – Recruitment closed. 86 patients participating.
Goal-Orientated Cognitive Rehabilitation in Early Stage Alzheimer’s and Related Dementias: Multi-Centre Single-Blind Randomised Controlled Trial.
The GREAT project aims to provide definite evidence about whether goal-orientated cognitive rehabilitation is a clinically-effective and cost-effective intervention for people with early-stage Alzheimer’s disease, Vascular dementia or mixed dementia, and for their carers.
*This is not a clinical trial so does not involve taking a specific medication.
Patients with early-stage Alzheimer’s disease, Vascular dementia or mixed dementia – no lower or upper age limit
Mini Mental State Examination (MMSE) score of 18 or above.
RICE has also been involved in a study with another of the drugs mentioned in the Horizon programme, crenezumab, but we are waiting to hear the results of this.
We are also currently recruiting to two other studies not featured in the programme:
A Phase 3, double-blind, randomized study of RVT-101 versus placebo when added to existing stable donepezil treatment in subjects with mild to moderate Alzheimer’s disease.
Healthy volunteers aged 50-85
Mini Mental State Examination (MMSE) score of 12-24
A multi-centre, double-blind, parallel-group, randomised controlled study to investigate efficacy, safety and tolerability of orally administered BI 409306 once or twice daily during a 12-week treatment period compared to donepezil and placebo in patients with mild Alzheimer’s Disease.
Healthy volunteers aged 55-85
Mini Mental State Examination (MMSE) score of 18-26
View All News »